Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded on December 11, 2020 and is headquartered in Cupertino, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

BARK

Graybug Vision

Revelation Biosciences

Hot penny stocks to watch this week. The post Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Penny Stocks To Watch: Why REVB, RVPH, BARK, and GRAY Stock Are Moving

Enrollment remains on pace for Reviva's Phase 3 clinical trial for the treatment of schizophrenia at 15 sites across the US with enrollment set to begin at sites in Europe and India in Q3 2022

Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline

CUPERTINO, Calif.,, June 02, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the 2022 BIO International Convention, to be held June 13-16 in San Diego, CA. Please see additional details below:

Reviva Pharmaceuticals to Participate in the 2022 BIO International Convention

CUPERTINO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright Global Investment Conference being held May 23–26, 2022 and invites investors to participate via virtual one-on-one meetings or in-person in Miami, FL. Please see additional details below:

Reviva Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

- Hosted key opinion leader (KOL) webinar on brilaroxazine for schizophrenia and other neuropsychiatric disorders led by industry thought leaders Leslie Citrome, MD &  Larry Ereshefsky, PharmD

Reviva Pharmaceuticals Holdings, Inc. Reports First Quarter 2022 Financial Results and Recent Business Highlights

CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that the RECOVER study is progressing well and all sites in the United States (U.S.) have been initiated. Global sites in Europe and India remain on track to initiate in mid-2022.

Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study Evaluating Brilaroxazine for the Treatment of Schizophrenia

CUPERTINO, Calif., March 24, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), respiratory and metabolic diseases, today announced that an interview with Founder, President and CEO Dr. Laxminarayan Bhat will air on The RedChip Money Report® on Bloomberg TV, March 26, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the United States.

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report®

CUPERTINO, Calif., March 22, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat and one-on-one investor meetings at the Maxim Virtual Growth Conference, to be held March 28-30, 2022. Please see additional details below:

Reviva Pharmaceuticals Holdings, Inc. to Participate at the Maxim Virtual Growth Conference

- 5 th Annual Neuroscience Innovation Forum -

Reviva Pharmaceuticals Holdings, Inc. to Present at Upcoming Virtual Investor Conferences

- Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia anticipated in mid-2023

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2021 Financial Results and Recent Business Highlights

- RECOVER is a Phase 3, randomized, double-blind study with registrational intent -

Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and Long-Term Safety Trial Evaluating Brilaroxazine for the Treatment of Schizophrenia

Dogness

Pluristem Therapeutics

Check these three penny stocks out for your January watchlist The post Best Penny Stocks to Buy Right Now? 3 For Your List in January appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy Right Now? 3 For Your List in January

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia. The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia.

FDA Gives Green Signal To Reviva Pharma's Late-Stage Schizophrenia Trial

- Brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications -

Reviva Pharmaceuticals Holdings, Inc. Receives FDA May Proceed Letter for Pivotal Phase 3 Clinical Trial and Long-Term Safety Trial Evaluating Brilaroxazine For The Treatment of Schizophrenia

CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:

Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

- Initiation of a pivotal Phase 3 trial evaluating the efficacy and safety of brilaroxazine for the treatment of schizophrenia expected by year-end -

Reviva Pharmaceuticals Holdings, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Highlights

CUPERTINO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the H.C. Wainwright 23rd Annual Global Investment Conference as well as participate in one-on-one meetings with investors. The Conference will be held virtually with all participants joining remotely from September 13th - 15th.

Reviva Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

-Closed Underwritten Public Offering of Common Stock and Warrants Resulting in Gross Proceeds of $34.5 Million

Reviva Pharmaceuticals Holdings, Inc. Reports Second Quarter 2021 Financial Results and Recent Business Highlights

Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) is trading higher with around 60k in session volume. Maxim initiated coverage of Reviva with a Buy rating and $10 price target, equivalent to an upside of around 140%.

Reviva Pharma Stock Is Trading Higher After Maxim Initiated With Buy, Target Price Of $10

CUPERTINO, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (along with its subsidiaries, “Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, announced today it has joined the broad-market Russell Microcap® Index at the conclusion of the Russell U.S. Indexes annual reconstitution. The updated Index will become effective after the U.S. equity market opens today, Monday June 28, 2021.

Reviva Added to Russell Microcap® Index

AMC Entertainment

1847 GOEDEKER INC.

Rezolute

Vertex Energy

Here is an overview of 5 of the top stock gainers for May 21 and why the stock prices moved. The post 5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH appeared first on Pulse 2.0.

5 Stock Gainers For May 27: VTNR, GOED, RZLT, AMC, RVPH

The stock price of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) decreased by over 11% pre-market. This is why it happened.

RVPH Stock Price: Over 11% Decrease Pre-Market Explanation

CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, announced today the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying investor warrants to purchase up to 6,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase 0.75 shares of common stock at a combined effective price of $3.75. The investor warrants will be immediately exercisable at an exercise price of $4.125 per share of common stock and will expire five years from the date of issuance. The offering is expected to close on June 1, 2021, subject to customary closing conditions. In addition, Reviva has granted the underwriters a 45-day option to purchase an additional 1,200,000 shares of common stock and/or investor warrants to purchase up to an additional 900,000 shares of common stock at the public offering price less discounts and commissions.

Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering

Today, investors in RVPH stock saw some pretty massive gains, as the company announced impressive results for its schizophrenia drug. The post RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday appeared first on InvestorPlace.

RVPH Stock: Why Reviva Pharmaceuticals Is Skyrocketing 90% on Monday

Axsome Therapeutics

uniQure

Voyager Therapeutics

CRISPR Therapeutics

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCRSP) are among the biggest biotech movers in Monday's session.

News for Reviva Pharmaceuticals Stock (RVPH)